Mary Harney
Follow
Get notifications in MyBN when activity occurs.
Mary Harney
Non-Executive Director / Race Oncology
Mary Harney is a company director with commercial experience, based on multiple years developing assets in oncology and the healthcare landscape. She has an understanding of academic and applied life science research, in addition to biopharmaceutical regulatory affairs and commercialization experience.
Ms Harney is the director of specialist consulting firm Mary Harney Advisory, providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture.
She is chair of private Australian biotech CTxONE, a cancer drug discovery and development company pursuing novel epigenetic and immuno-oncology programs.
Ms Harney was the chief executive of Royal Australasian College of Surgeons and Gardiner Research Foundation, chief operating officer and director of the Office of Cancer Research for Peter MacCallum Hospital, and chief operating officer of Cerylid Biosciences.
In 2017, Ms Harney completed 'Strategy in the Age of Digital Disruption' at INSEAD Business School.
Ms Harney is the director of specialist consulting firm Mary Harney Advisory, providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture.
She is chair of private Australian biotech CTxONE, a cancer drug discovery and development company pursuing novel epigenetic and immuno-oncology programs.
Ms Harney was the chief executive of Royal Australasian College of Surgeons and Gardiner Research Foundation, chief operating officer and director of the Office of Cancer Research for Peter MacCallum Hospital, and chief operating officer of Cerylid Biosciences.
In 2017, Ms Harney completed 'Strategy in the Age of Digital Disruption' at INSEAD Business School.
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 287th | Race Oncology | 57% | 62% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Race Oncology | $4.0m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEWS: Tagged in Board moves September 3, 20224 | 03 Sep 2024 |
| NEW ROLE: Non-Executive Director, INOVIQ | 03 Sep 2024 |
| NEW ROLE: Non-Executive Director, Race Oncology | 16 Apr 2021 |
